The Effect of Cannabidiol on ischemia/reperfusion-induced ventricular arrhythmias: The role of adenosine a1 receptors

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 20, Issue 1, 2015, Pages 76-83

  Gonca, Ersöz ^a   Darici, Faruk ^a  

^a ZONGULDAK KARAELMAS UNIVERSITY   (Turkey)

Author keywords

Anesthetized rats; Cannabidiol; Ischemia reperfusion arrhythmias

Indexed keywords

8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENOSINE A1 RECEPTOR; CANNABIDIOL; ANTIARRHYTHMIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFECT; DRUG MECHANISM; EXPERIMENTAL ARRHYTHMIA; EXPERIMENTAL CORONARY OCCLUSION; EXPERIMENTAL MYOCARDIAL ISCHEMIA; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; INCIDENCE; MALE; NONHUMAN; PROTEIN FUNCTION; RAT; RECEPTOR UPREGULATION; REPERFUSION INJURY; ANIMAL; ARRHYTHMIAS, CARDIAC; METABOLISM; MYOCARDIAL REPERFUSION INJURY; PHYSIOLOGY; TREATMENT OUTCOME; WISTAR RAT;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; CANNABIDIOL; MALE; MYOCARDIAL REPERFUSION INJURY; RATS; RATS, WISTAR; RECEPTOR, ADENOSINE A1; TREATMENT OUTCOME;

EID: 84916620045     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248414532013     Document Type: Article

References (44)

1. Bonnemeier H, Wiegand UK, Giannitsis E, et al. Temporal repolarization inhomogeneity and reperfusion arrhythmias in patients undergoing successful primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: impact of admission troponin T. Am Heart J. 2003;145(3):484-492.
2. Tatli E, Alicik G, Buturak A, Yilmaztepe M, Aktoz M. Arrhythmias following Revascularization Procedures in the Course of Acute Myocardial Infarction: are they indicators of reperfusion or ongoing ischemia? Sci World J. 2013;2013:160380. doi:10.1155/2013/160380.
3. Mechoulam R, Peters M, Murillo-Rodriguez E, Honus LO. Cannabidiol-recent advances. Chem Biodivers. 2007;4(8):1678-1692.
4. Bergamaschi MM, Queiroz RH, Zuardi AW, Crippa JA. Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr Drug Saf. 2011;6(4):237-249.
5. Lorente Fernández L, Monte Boquet E, Pérez-Miralles F, et al. Clinical experiences with cannabinoids in spasticity management in multiple sclerosis. Neurologia. 2013;10:213-4853.
6. Valdeolivas S, Satta V, Pertwee RG, Fernández-Ruiz J, Sagredo O. Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors. ACS Chem Neurosci. 2012;3(5):400-406.
7. Peat S. Using cannabinoids in pain and palliative care. Int J Palliat Nurs. 2010;16(10):481-485.
8. Naftali T, Bar-Lev SL, Dotan I, Lansky EP, Sklerovsky BF, Konikoff FM. Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study. Clin Gastroenterol Hepatol. 2013;11(10):1276-1280.
9. Stanley CP, Hind WH, O'Sullivan SE. Is the cardiovascular system a therapeutic target for cannabidiol? Br J Clin Pharmacol. 2013;75(2):313-322.
10. Durst R, Danenberg H, Gallily R, et al. Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury. Am J Physiol Heart Circ Physiol. 2007;293(6):3602-3607.
11. Walsh SK, Hepburn CY, Kane KA, Wainwright CL. Acute administration of cannabidiol in vivo suppresses ischaemia-induced cardiac arrhythmias and reduces infarct size when given at reperfusion. Br J Pharmacol. 2010;160(5):1234-1242.
12. Bisogno T, Hanus L, De Petrocellis L, et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol. 2001;134(4):845-852.
13. Ryberg E, Larsson N, Sjögren S, et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol. 2007; 152(7):1092-1101.
14. Zhong B, Wang DH. Protease-activated receptor 2-mediated protection of myocardial ischemia-reperfusion injury: role of transient receptor potential vanilloid receptors. Am J Physiol Regul Integr Comp Physiol. 2009;297(6):1681-1690.
15. Carrier EJ, Auchampach JA, Hillard CJ. Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci USA. 2006;103(20):7895-7900.
16. Ribeiro A, Ferraz-de-Paula V, Pinheiro ML, et al. Cannabidiol, a non-psychotropic plant-derived cannabinoid, decreases inflammation in a murine model of acute lung injury: role for the adenosine A(2A) receptor. Eur J Pharmacol. 2012;678(1-3):78-85.
17. Downey JM, Davis AM, Cohen MV. Signaling pathways in ischemic preconditioning. Heart Fail Rev. 2007;12(3-4): 181-188.
18. Liu GS, Thornton J, Van Winkle DM, Stanley AWH, Olsson RA, Downey JM. Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart. Circulation. 1991;84(1):350-356.
19. Cohen MV, Baines CP, Downey JM. Ischemic preconditioning: from adenosine receptor to KATP channel. Annu Rev Physiol. 2000;62:79-109.
20. Bozdogan O, Gonca E, Ekerbic¸er N. Effects of adenosine A1 receptor agonist CCPA and antagonist DPCPX on ischemia/ reperfusion-induced arrhythmias in rats. Turk J Med Sci. 2010; 40(2):249-256.
21. Wainwright CL, Parratt JR. Effects of R-PIA, a selective A1 adenosine agonist, on haemodynamics and ischaemic arrhythmias in pigs. Cardiovasc Res. 1993;27(1):84-89.
22. Canyon SJ, Dobson GP. Pretreatment with an adenosine A1 receptor agonist and lidocaine: a possible alternative to myocardial ischemic preconditioning. J Thorac Cardiovasc Surg. 2005; 130(2):371-377.
23. Bozdoʇan O, Gonca E, Suveren E, Nebigil M. Effect of thimerosal on arrhythmia induced by coronary ligation. Int Heart J. 2005; 46(4):711-721.
24. Vajda S, Baczkó I, Leprán I. Selective cardiac plasma-membrane K-ATP channel inhibition is defibrillatory and improves survival during acute myocardial ischemia and reperfusion. Eur J Pharmacol. 2007;577(1-3):115-123.
25. Kin H, Zatta AJ, Lofye MT, et al. Postconditioning reduces infarct size via adenosine receptor activation by endogenous adenosine. Cardiovasc Res. 2005;67(1):124-133.
26. Walker MJ, Curtis MJ, Hearse DJ, et al. The Lambeth Conventions: guidelines for the study of arrhythmias in ischemia infarction and reperfusion. Cardiovasc Res. 1988;22(7):447-455.
27. Lepran I, Koltai M, Siegmund W, Szekeres L. Coronary artery ligation, early arrhythmias, and determination of the ischemic area in conscious rats. J Pharmacol Methods. 1983;9(3):219-230.
28. Otani N, Matsuda R, Oda K, Nishino S, Inoue T, Kaneko N. Protective effect of K201 on isoproterenol-induced and ischemic-reperfusion-induced ventricular arrhythmias in the rat: comparison with diltiazem. J Cardiovasc Pharmacol Ther. 2013;18(2): 184-190.
29. Ek RO, Yildiz Y, Cecen S, Yenisey C, Kavak T. Effects of tamoxifen on myocardial ischemia-reperfusion injury model in ovariectomized rats. Mol Cell Biochem. 2008;308(1-2): 227-235.
30. Gonca E, Bozdoʇan O. Both mitochondrial KATP channel opening and sarcolemmal KATP channel blockage confer protection against ischemia/reperfusion induced arrhythmia in anesthetized male rats. J Cardiovasc Pharmacol Ther. 2010;15(4):403-411.
31. Gonca E. The effects of zileuton and montelukast in reperfusioninduced Arrhythmias in anesthetized rats. Curr Ther Res Clin Exp. 2013;75:27-32.
32. Tan HL, Spekhorst HHM, Peters RJG, Wilde AAM. Adenosine induced ventricular arrhythmias in the emergency room. Pacing Clin Electrophysiol. 2001;24(4 pt 1):450-455.
33. Schreieck J, Richardt G. Endogenous adenosine reduces the occurrence of ischemia-induced ventricular fibrillation in rat heart. J Mol Cell Cardiol. 1999;31(1):123-134.
34. Bozdoʇan Ö, Gonca E, Ekerbic¸er N. Effects of adenosine A1 receptor agonist CCPA and antagonist DPCPX on ischemia/reperfusioninduced arrhythmias in rats. Turk J Med Sci. 2010;40(1):1-8.
35. Lee YM, Chern JW, Yen MH. Antiarrhythmic effects of BN-063, a newly synthesized adenosine A1 agonist, on myocardial ischemia in rats. Br J Pharmacol. 1994;112(4):1031-1036.
36. Mamas MA, Terrar DA. Differential sensitivity to cannabidiol of the two components of delayed rectifier potassiumcurrents inguinea pig isolated ventricular myocytes. Br J Pharmacol. 1998;123:319.
37. Tamargo J, Caballero R, Gomez R, Valenzuela C, Delpon E. Pharmacology of cardiac potassium channels. Cardiovasc Res. 2004;62(1):9-33.
38. Varro A, Lathrop DA, Hester SB, Nanasi PP, Papp JG. Ionic currents and action potentials in rabbit, rat, and guinea pig ventricular myocytes. Basic Res Cardiol. 1993;88(2):93-102.
39. Hepburn CY, Walsh SK, Wainwright CL. Cannabidiol as an anti-arrhythmic, the role of the CB1 receptors. Heart. 2011; 97(24):e8. doi:10.1136/heartjnl-2011-301156.17.
40. Canyon SJ, Dobson GP. Pretreatment with an adenosine A1 receptor agonist and lidocaine: a possible alternative to myocardial ischemic preconditioning. J Thorac Cardiovasc Surg. 2005; 130(2):371-377.
41. Kirsch GE, Codina J, Birnbaumer L, Brown AM. Coupling of ATP sensitive K channels to A1 receptors by G proteins in rat ventricular myocytes. Am J Physiol Heart Circ Physiol. 1990; 259(3 pt 2):820-826.
42. Nakaya H. Role of ATP-sensitive K+ channels in cardiac arrhythmias. J Cardiovasc Pharmacol Ther. 2014;19(3):237-243.
43. Wainwright CL, Parratt JR, Van Belle H. The antiarrhythmic effects of the nucleoside transporter inhibitor, R75231, in anaesthetized pigs. Br J Pharmacol. 1993;109(2):592-599.
44. Yoshida Y, Hirai M, Yamada T, et al. Antiarrhythmic efficacy of dipyridamole in treatment of reperfusion arrhythmias: evidence for cAMP-mediated triggered activity as a mechanism responsible for reperfusion arrhythmias. Circulation. 2000; 101(6):624-630.